Lpl Financial LLC Kempharm, Inc Transaction History

Lpl Financial LLC

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	N/A	-2,809 Reduced 17.21%	13,515 $66,000
Q2 2024 Aug 07, 2024	BUY	N/A	267 Added 1.66%	16,324 $80,000
Q1 2024 May 10, 2024	SELL	N/A	-707 Reduced 4.22%	16,057 $79,000
Q4 2023 Feb 14, 2024	SELL	N/A	-2,829 Reduced 14.44%	16,764 $82,000
Q3 2023 Nov 13, 2023	BUY	N/A	4,062 Added 26.15%	19,593 $96,000
Q2 2023 Jul 31, 2023	SELL	$4.94 - $6.29 $6,175 - $7,862	-1,250 Reduced 7.45%	15,531 $76,000
Q1 2023 May 10, 2023	BUY	$4.13 - $6.27 $26,560 - $40,322	6,431 Added 62.14%	16,781 $92,000
Q4 2022 Feb 07, 2023	SELL	$4.12 - $5.62 $1,442 - $1,967	-350 Reduced 3.27%	10,350 $47,000
Q3 2022 Nov 14, 2022	BUY	$4.5 - $6.85 $900 - $1,370	200 Added 1.9%	10,700 $67,000
Q2 2022 Aug 12, 2022	SELL	$4.02 - $5.21 $200 - $260	-50 Reduced 0.47%	10,500 $47,000
Q1 2022 May 16, 2022	BUY	$5.0 - $9.26 $52,750 - $97,693	10,550 New	10,550 $53,000
Q3 2021 Nov 15, 2021	SELL	$8.72 - $13.31 $115,540 - $176,357	-13,250 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.52 - $15.47 $112,890 - $204,977	13,250 New	13,250 $170,000

115

30.2M

284K

24.1K

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.